First-in-Class Diabetes Drug Approved

Share this article:

The FDA has approved Invokana (canagliflozin), a first-in-class medication that helps to improve glycemic control in adults with type 2 diabetes.

Manufactured by Janssen Pharmaceuticals based in Raritan, N.J., canagliflozin is a sodium-glucose co-transporter 2 inhibitor that blocks reabsorption of glucose in the kidney, increases glucose excretion, and lowers blood glucose levels.

The drug was studied in combination with other treatments for type 2 diabetes, including metformin, sulfonylurea, pioglitazone, and insulin across nine clinical trials that included 10,285 patients. From the trials, researchers noted an improvement in hemoglobin A1c levels and fasting plasma glucose levels in addition to reduced body weight and systolic blood pressure.

Share this article:
You must be a registered member of RUN to post a comment.

More in Diabetes

Diabetes Prevalence Has Skyrocketed in the Last Two Decades

Diabetes Prevalence Has Skyrocketed in the Last Two ...

Prevalence higher and glycemic control poorer in non-Hispanic blacks and Mexican-Americans.

New Diabetes Drug Approved

New Diabetes Drug Approved

FDA clears albiglutide as an adjunct to diet and exercise for glycemic control in adult type 2 diabetes patients.

Glucose Levels Established for Hemoglobin Targets

Glucose Levels Established for Hemoglobin Targets

Average blood glucose levels at premeal, postmeal, bedtime established for achieving HbA1c targets.